

Pre-operative oral supplementation in colorectal cancer patients

Submission date 03/11/2011	Recruitment status No longer recruiting	☒ Prospectively registered ☐ Protocol
Registration date 23/01/2012	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 05/06/2019	Condition category Cancer	☐ Individual participant data

Plain English summary of protocol

<http://cancerhelp.cancerresearchuk.org/trials/a-trial-looking-food-supplement-drinks-people-bowel-cancer-related-weight-loss-posicc>

Contact information

Type(s)

Scientific

Contact name

Dr Sorrel Burden

ORCID ID

<https://orcid.org/0000-0002-4967-647X>

Contact details

Room 6.308
Jean Macfarlane Building
University of Manchester
Oxford Road
Manchester
United Kingdom
M13 9PL
+44 (0)161 306 7856
sorrel.burden@manchester.ac.uk

Additional identifiers

Protocol serial number

101

Study information

Scientific Title

A randomised controlled trial for Pre-operative Oral Supplementation in Colorectal Cancer patients

Acronym

POSiCC

Study objectives

Do oral nutritional supplements and dietary advice compared to dietary advice alone improve clinical outcomes in weight losing colorectal cancer patients?

Are oral supplements and dietary advice cost effective for weight losing colorectal cancer patients compared to dietary advice alone?

Ethics approval required

Old ethics approval format

Ethics approval(s)

NRES Committee- North West Liverpool East, 15 March 2012, ref: 12/NM/0208

Primary study design

Interventional

Study design

Pragmatic randomised controlled trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Colorectal cancer

Interventions

The intervention will be in the form of an oral supplement, if patients can tolerate milky drinks Fortisip Compact® (Nutricia Clinical Care) will be used. Patients will be offered a minimum of 250mls of supplement daily (2.4Kcals or 10.1KJ and 0.096g of protein per ml).

If patients cannot tolerate milky drinks they will be offered Fortijuce® as an alternative (Nutricia Clinical Care) and asked to consume 400mls of supplement per day (1.5Kcals or 6.3KJ and 0.04g protein per ml, Fortijuce®).

Patients will be started on the sip feed at the point of diagnosis of a colorectal tumour and when surgery is considered likely to be the treatment option. It is anticipated that the patients will receive the oral supplement for a minimum of two weeks and a maximum of 12 weeks. Patients will be asked to take the supplement up until they are placed on the preoperative carbohydrate drinks prior to surgery.

Patients randomised will either be given dietary advice or oral supplements and dietary advice. The dietary advice will be to increase calories and protein in the diet. Patients will be given a diet sheet on increasing energy and protein in the diet. This advice is appropriate for weight losing patients preoperatively.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Fortisip Compact® , Fortijuice®

Primary outcome(s)

Number of postoperative chest and surgical site infections after CRC surgery, measured from patient medical records reviewed within 30 days after surgery.

Key secondary outcome(s)

As of 17/03/2016:

1. Total complications measured up to 30 days postoperatively
2. Anthropometry
3. Body composition and dietary intake

Measured at baseline, 2-3 days preoperatively (where possible) and 7-10 days postoperatively (where possible).

Initial

1. Anthropometry height, weight, body mass index, mid arm circumference (MAC) and skin fold thickness
2. Hand grip strength
3. Co-morbidities
4. 24 hour recalls to assess energy and protein
5. Hospital anxiety and depression score

Measured at baseline, 24 hours preoperatively, 7 days post-operatively and at 3 months

Completion date

30/12/2013

Eligibility**Key inclusion criteria**

1. Reported weight loss over the previous 6 months
2. Primary colorectal tumour, eligible for curative surgery
3. Informed consent gained

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Pregnant or enrolled in another trial
2. Pacemaker and any metallic implant will preclude individuals from bioelectrical impedance monitoring
3. Cannot give informed consent

Date of first enrolment

10/10/2012

Date of final enrolment

22/01/2015

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Room 6.308

Manchester

United Kingdom

M13 9PL

Sponsor information

Organisation

University of Manchester (UK)

ROR

<https://ror.org/027m9bs27>

Funder(s)

Funder type

Charity

Funder Name

Macmillan Cancer Care (UK)

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/06/2017		Yes	No
Plain English results				No	Yes